<DOC>
	<DOCNO>NCT01754259</DOCNO>
	<brief_summary>Coronary vascular dysfunction highly prevalent among patient know suspected Coronary Artery Disease ( CAD ) 1 , increase severity inducible myocardial ischemia ( beyond effect upstream coronary obstruction ) 2 , identifies patient high risk serious adverse event , include cardiac death1 , 3-5 . Diabetic patient without know CAD impaired coronary vascular function show risk cardiac death comparable , possibly high , non-diabetic patient know CAD10 . In set increased oxygen demand , coronary vasodilator dysfunction upset supply-demand relationship lead myocardial ischemia , subclinical leave ventricular dysfunction ( diastolic systolic ) , symptom . The significance microvascular coronary dysfunction increasingly recognize invasive non-invasive ( PET ) method quantify CFR become available . Importantly , current treatment strategy obstructive CAD , percutaneous coronary intervention angioplasty stenting , helpful microvascular disease . Similarly , mortality-altering treatment systolic heart failure , angiotensin convert enzyme inhibitor , beneficial treat diastolic dysfunction .</brief_summary>
	<brief_title>Effects Ranolazine Coronary Flow Reserve Symptomatic Diabetic Patients CAD</brief_title>
	<detailed_description>Ranolazine novel anti-anginal agent inhibits late sodium current cardiomyocytes , decrease sodium calcium overload . In ischemia , excess intracellular calcium may impair myocyte relaxation contribute ventricular diastolic stiffness , turn affect myocardial contractility perfusion . Ranolazine FDA-approved treatment chronic angina . In three randomized , placebo-controlled trial patient stable angina , show increase exercise time free angina ST-segment depression , increase exercise capacity decrease angina use combination establish antianginal agent include diltiazem , amlodipine atenolol , reduce frequency angina patient maximum dos amlodipine.Similarly , large population patient acute coronary syndrome , ranolazine also decrease exertional angina symptom incidence arrhythmia , effect mortality . Interestingly , study , significantly improve hemoglobin A1c recurrent ischemia patient diabetes mellitus , reduce incidence increase hemoglobin A1c patient without know prior hyperglycemia . Although anti-ischemic effect ranolazine think mediated part increase myocardial blood flow , currently limited evidence effect tissue perfusion . A previous study woman without overt CAD detect improve myocardial blood flow treatment ranolazine . In study , however , coronary hyperemia elicit adenosine ( uncouples blood flow cardiac work , reflect predominantly endothelial-independent vasodilation ) rather exercise , trigger complex interplay metabolic demand , coronary hemodynamics , vasodilator response . Thus , need additional investigation whether beneficial effect ranolazine exertional symptom directly relate improve global tissue perfusion . Such evidence would support use ranolazine anti-ischemic therapy challenge population symptomatic patient evidence microvascular dysfunction without obstructive CAD .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Inclusion Criteria 1. type 1 2 diabetes mellitus 2. anginal symptom and/or exertional dyspnea ; 3. ability exercise achieve exercise tolerance least 3 METS high 9 METS either treadmill bicycle exercise tolerance test ; 4. perfusion sum stress score ( SSS ) ≤ 6 , assess initial PET Exclusion Criteria 1. patient fulfil inclusion criterion 2. patient evidence unprotected leave main coronary artery stenosis &gt; 50 % 3. patient evidence new obstructive CAD optimal medical therapy 4. evidence angiographic disease and/or inducible myocardial ischemia stress test plan undergo revascularization within follow 3 month 5. history cardiomyopathy ( LVEF &lt; 40 % ) significant valvular heart disease 6. uncontrolled hypertension ( SBP &gt; 180 mm Hg screening ) 7. gait instability , low extremity amputation prevent exercise 9. significant liver dysfunction ( LFTs &gt; 3x upper limit normal ) , include cirrhosis 10. prolonged QT ( QTc &gt; 450 &gt; 470 m men woman , respectively ) concomitant use drug prolong QT interval ( include methadone antiarrhythmic sotalol , amiodarone , quinidine ) 11. use drug inhibit CYP3A ketoconazole , itraconazole , fluconazole , clarithromycin , erythromycin , diltiazem , verapamil , nefazodone , nelfinavir , ritonavir , lopinavir , ritonavir , indinavir , saquinavir 12. use drug induce CYP3A rifampin , rifabutin , rifapentine , phenobarbital , phenytoin , carbamazepine , St. John 's wort 13. atrial fibrillation / inability hold breath ≥ 10 second ( patient CTA perform ) 14. eGFR &lt; 50 ml/min end stage renal disease dialysis 15. allergy intravenous contrast 16. pregnant lactate woman , woman childbearing potential use acceptable form birth control ( negative pregnancy test also require ) 17. inability fit safely PET/CT scanner</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>exertion angina</keyword>
	<keyword>suspect CAD</keyword>
	<keyword>know CAD</keyword>
</DOC>